Saturday 17 October 2026
Export APVO’s income statement to Excel — free account
Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.62
0.08
−4.71%
Follow APVO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(256.30%) | (248.81%) | (550.82%) | (446.89%) | |
| (132.66%) | (128.73%) | (197.73%) | (186.29%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(160.47%) | (158.87%) | (242.99%) | (480.26%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(116.02) | (81.12) | (25.44) | (21.18) | |
Free Cash Flow |
(26.11) | (25.59) | (26.98) | (25.34) | |
| Other line items | |||||
Cash ROIC |
(67.91%) | (65.62%) | (103.23%) | (160.01%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.93 | 0.93 | 0.97 | 0.90 | |
Depreciation/Fixed assets |
0.60 | 0.79 | 0.80 | 0.83 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(116.02) | (81.12) | (25.44) | (21.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates